share_log

Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting

Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting

阿卡迪亞製藥在2024年IRSF年會上展示霞症的DAYBUE實際證據和其他數據
Benzinga ·  06/18 09:29

Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE (trofinetide).

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論